Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews
- PMID: 15525722
- DOI: 10.1056/NEJMoa033277
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews
Abstract
Background: A clinical association has been reported between type 1 Gaucher's disease, which is caused by a glucocerebrosidase deficiency owing to mutations in the glucocerebrosidase gene (GBA), and parkinsonism. We examined whether mutations in the GBA gene are relevant to idiopathic Parkinson's disease.
Methods: A clinic-based case series of 99 Ashkenazi patients with idiopathic Parkinson's disease, 74 Ashkenazi patients with Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent testing to identify heterozygosity for certain recessive diseases were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1, V394L, and R496H) that are most common among Ashkenazi Jews.
Results: Thirty-one patients with Parkinson's disease (31.3 percent; 95 percent confidence interval, 22.2 to 40.4 percent) had one or two mutant GBA alleles: 23 were heterozygous for N370S, 4 were heterozygous for 84GG, 3 were homozygous for N370S, and 1 was heterozygous for R496H. Among the 74 patients with Alzheimer's disease, 3 were identified as carriers of Gaucher's disease (4.1 percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five carriers of Gaucher's disease were identified among the 1543 control subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4 percent): 92 were heterozygous for N370S, and 3 were heterozygous for 84GG. Patients with Parkinson's disease had significantly greater odds of being carriers of Gaucher's disease than did patients with Alzheimer's disease (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0; 95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the patients with Parkinson's disease, patients who were carriers of Gaucher's disease were younger than those who were not carriers (mean [+/-SD] age at onset, 60.0+/-14.2 years vs. 64.2+/-11.7 years; P=0.04).
Conclusions: Our results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.
Copyright 2004 Massachusetts Medical Society.
Comment in
-
New genetic insights into Parkinson's disease.N Engl J Med. 2004 Nov 4;351(19):1937-40. doi: 10.1056/NEJMp048263. N Engl J Med. 2004. PMID: 15525720 No abstract available.
-
The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.N Engl J Med. 2005 Feb 17;352(7):728-31; author reply 728-31. doi: 10.1056/NEJM200502173520719. N Engl J Med. 2005. PMID: 15716572 No abstract available.
-
The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.N Engl J Med. 2005 Feb 17;352(7):728-31; author reply 728-31. N Engl J Med. 2005. PMID: 15719451 No abstract available.
-
The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.N Engl J Med. 2005 Feb 17;352(7):728-31; author reply 728-31. N Engl J Med. 2005. PMID: 15719452 No abstract available.
Similar articles
-
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.Brain. 2015 Sep;138(Pt 9):2648-58. doi: 10.1093/brain/awv179. Epub 2015 Jun 27. Brain. 2015. PMID: 26117366 Free PMC article.
-
Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity.Mov Disord. 2005 Jan;20(1):100-3. doi: 10.1002/mds.20320. Mov Disord. 2005. PMID: 15517591
-
Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population.Hum Mutat. 1998;12(4):240-4. doi: 10.1002/(SICI)1098-1004(1998)12:4<240::AID-HUMU4>3.0.CO;2-J. Hum Mutat. 1998. PMID: 9744474
-
Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.Neurochem Int. 2016 Feb;93:6-25. doi: 10.1016/j.neuint.2015.12.004. Epub 2015 Dec 30. Neurochem Int. 2016. PMID: 26743617 Review.
-
Mutations in GBA and risk of Parkinson's disease: a meta-analysis based on 25 case-control studies.Neurol Res. 2013 Oct;35(8):873-8. doi: 10.1179/1743132813Y.0000000224. Epub 2013 May 14. Neurol Res. 2013. PMID: 23676350 Review.
Cited by
-
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.Brain. 2015 Sep;138(Pt 9):2648-58. doi: 10.1093/brain/awv179. Epub 2015 Jun 27. Brain. 2015. PMID: 26117366 Free PMC article.
-
GBA1-Associated Parkinson's Disease Is a Distinct Entity.Int J Mol Sci. 2024 Jun 28;25(13):7102. doi: 10.3390/ijms25137102. Int J Mol Sci. 2024. PMID: 39000225 Free PMC article. Review.
-
Characterization of a pathogenic variant in GBA for Parkinson's disease with mild cognitive impairment patients.Mol Brain. 2020 Jul 8;13(1):102. doi: 10.1186/s13041-020-00637-x. Mol Brain. 2020. PMID: 32641146 Free PMC article.
-
Lysosomal size matters.Traffic. 2020 Jan;21(1):60-75. doi: 10.1111/tra.12714. Epub 2019 Dec 6. Traffic. 2020. PMID: 31808235 Free PMC article. Review.
-
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.Mol Genet Metab. 2020 Feb;129(2):35-46. doi: 10.1016/j.ymgme.2019.10.006. Epub 2019 Oct 23. Mol Genet Metab. 2020. PMID: 31761523 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical